Triple Combination Therapy of Choroidal Neovascularization in Exudative Age-related Macular Degeneration - a Cost Effect and Efficient Therapeutic Treatment
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- BEST CORRECTED VISUAL ACUITY
Study Overview
Brief Summary
We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during the years of 2006 to 2010 at The Retina Center and compare those results with an additional group of approximately 200 patients also treated with triple combination therapy and 20 mg of daily oral zeaxanthin.
Detailed Description
Study parameters will include best corrected visual acuity, number of combination treatments, reduction of central foveal thickness by OCT measurement and development of exudative macular degeneration in the fellow eye. Follow up will include all patients with a minimum of two years. Retrospective review of patient charts in the office of The Retina Center.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 50 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •MUST HAVE AGE RELATED MACULAR DEGENERATION
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
BEST CORRECTED VISUAL ACUITY
Time Frame: REVIEW OF EXAMINATION SHEETS
Secondary Outcomes
- DEVELOPMENT OF EXUDATIVE MACULAR DEGENERATION IN THE FELLOW EYE(REVIEW OF CHART)
- REDUCTION OF CENTRAL FOVEAL THICKNESS BY OCT MEASUREMENT(REVIEW OF CHART)
- NUMBER OF COMBINATION TREATMENTS(REVIEW OF CHART)